{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:07:49Z","timestamp":1794640069678,"version":"4.9.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","license":[{"start":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:00:00Z","timestamp":1697760000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,20]]},"abstract":"<jats:p>Idiopathic intracranial hypertension (IIH) is a condition of unknown etiology that primarily affects obese women of childbearing age. Symptoms include disabling headaches, visual disturbances, and intracranial noises (pulsatile tinnitus). Currently, no standardized treatment guidelines are available and the current management focuses on weight loss and acetazolamide use. There is an increasing body of evidence suggesting that the initial use of topiramate may be considered in IIH treatment. Acetazolamide is the recommended initial treatment for IIH, with topiramate often used as a second-line agent. Topiramate has multiple benefits to indicate it would pose effective in IIH management. Through varying mechanisms, it leads to weight loss and improves migraine headache control, the most common headache phenotype in IIH. Topiramate also inhibits the carbonic anhydrase enzyme like acetazolamide to reduce intracranial pressure and treat papilledema. The safety profile of topiramate is comparable or superior to acetazolamide. To date, there are limited studies comparing topiramate to acetazolamide or other treatment modalities in IIH. Based on its varying mechanisms of action, topiramate is a strong potential treatment agent for IIH, yet acetazolamide is often chosen first-line. However, the data supporting use of acetazolamide or topiramate is inefficient to designate one agent preferred over the other. There is a need for further studies assessing topiramate use in the treatment of IIH, and comparing topiramate use to other treatment modalities.<\/jats:p>","DOI":"10.1097\/md.0000000000035545","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T15:21:44Z","timestamp":1697815304000},"page":"e35545","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":22,"title":["Should topiramate be initial therapy in the management of idiopathic intracranial hypertension?: A literature review"],"prefix":"10.1097","volume":"102","author":[{"given":"Abhishek","family":"Goyal","sequence":"first","affiliation":[{"name":"Kasturba Medical College, MAHE, Manipal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5676-0434","authenticated-orcid":false,"given":"Katherine","family":"Zarroli","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Florida College of Medicine - Jacksonville, Jacksonville, FL, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(15)00298-7","article-title":"Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions.","volume":"15","author":"Markey","year":"2016","journal-title":"Lancet Neurol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/s41433-018-0238-5","article-title":"The expanding burden of idiopathic intracranial hypertension.","volume":"33","author":"Mollan","year":"2019","journal-title":"Eye (Lond)"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"e1251","DOI":"10.1212\/WNL.0000000000011463","article-title":"Incidence, prevalence and healthcare outcomes in idiopathic intracranial hypertension: a population study.","volume":"96","author":"Miah","year":"2021","journal-title":"Neurology"},{"key":"R4-20250504","first-page":"CD003434","article-title":"Interventions for idiopathic intracranial hypertension.","volume":"2015","author":"Piper","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF01668270","article-title":"Ueber meningitis serosa und verwandte zust\u00e4nde.","volume":"9","author":"Quincke","year":"1897","journal-title":"Dtsch Z Nervenheilkd"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/00000658-193710000-00002","article-title":"Intracranial pressure without brain tumor: diagnosis and treatment.","volume":"106","author":"Dandy","year":"1937","journal-title":"Ann Surg"},{"key":"R7-20250504","first-page":"55","article-title":"Whence pseudotumor cerebri?","volume":"5","author":"Smith","year":"1985","journal-title":"J Clin Neuroophthalmol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1212\/WNL.0b013e3182a55f17","article-title":"Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children.","volume":"81","author":"Friedman","year":"2013","journal-title":"Neurology"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"c2701","DOI":"10.1136\/bmj.c2701","article-title":"Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study.","volume":"341","author":"Sinclair","year":"2010","journal-title":"BMJ"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1001\/jamaneurol.2021.0659","article-title":"Effectiveness of bariatric surgery vs community weight management intervention for the treatment of idiopathic intracranial hypertension: a randomized clinical trial.","volume":"78","author":"Mollan","year":"2021","journal-title":"JAMA Neurol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s10194-018-0919-2","article-title":"European Headache Federation guideline on idiopathic intracranial hypertension.","volume":"19","author":"Hoffmann","year":"2018","journal-title":"J Headache Pain"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s00415-010-5861-4","article-title":"A randomised controlled trial of treatment for idiopathic intracranial hypertension.","volume":"258","author":"Ball","year":"2011","journal-title":"J Neurol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/jama.2014.3312","article-title":"Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial.","volume":"311","author":"Wall","year":"2014","journal-title":"JAMA"},{"issue":"Suppl 1","key":"R14-20250504","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1157.2000.tb02163.x","article-title":"An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action.","volume":"41","author":"Shank","year":"2000","journal-title":"Epilepsia"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/oby.2003.78","article-title":"Predictors of weight loss in adults with topiramate-treated epilepsy.","volume":"11","author":"Ben-Menachem","year":"2003","journal-title":"Obes Res"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1111\/j.1467-789X.2010.00846.x","article-title":"Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials.","volume":"12","author":"Kramer","year":"2011","journal-title":"Obes Rev"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1038\/sj.npp.1300178","article-title":"Topiramate normalizes hippocampal NPY-LI in flinders sensitive line \u201cdepressed\u201d rats and upregulates NPY, galanin, and CRH-LI in the hypothalamus: implications for mood-stabilizing and weight loss-inducing effects.","volume":"28","author":"Husum","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/j.1651-2227.2009.01349.x","article-title":"Effects of topiramate on weight and metabolism in children with epilepsy.","volume":"98","author":"Li","year":"2009","journal-title":"Acta Paediatr"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"749050","DOI":"10.3389\/fendo.2021.749050","article-title":"The leptin system and diet: a mini-review of the current evidence.","volume":"12","author":"Mendoza","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/MJT.0b013e31813e65b7","article-title":"Is acetazolamide similar to topiramate for reversal of antipsychotic-induced weight gain?","volume":"14","author":"Schneiderhan","year":"2007","journal-title":"Am J Ther"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/14737175.2015.1066675","article-title":"Acetazolamide for the treatment of idiopathic intracranial hypertension.","volume":"15","author":"Supuran","year":"2015","journal-title":"Expert Rev Neurother"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/0333102418776455","article-title":"Topiramate is more effective than acetazolamide at lowering intracranial pressure.","volume":"39","author":"Scotton","year":"2019","journal-title":"Cephalalgia"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/head.13153","article-title":"Headache in idiopathic intracranial hypertension: findings from the idiopathic intracranial hypertension treatment trial.","volume":"57","author":"Friedman","year":"2017","journal-title":"Headache"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/ene.12512","article-title":"The course of headache in idiopathic intracranial hypertension: a 12-month prospective follow-up study.","volume":"21","author":"Yri","year":"2014","journal-title":"Eur J Neurol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eplepsyres.2011.05.014","article-title":"Topiramate-induced weight loss: a review.","volume":"95","author":"Verrotti","year":"2011","journal-title":"Epilepsy Res"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/jama.291.8.965","article-title":"Topiramate for migraine prevention: a randomized controlled trial.","volume":"291","author":"Brandes","year":"2004","journal-title":"JAMA"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/j.1526-4610.2006.00538.x","article-title":"Repression of stimulated calcitonin gene-related peptide secretion by topiramate.","volume":"46","author":"Durham","year":"2006","journal-title":"Headache"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1526-4637.2007.00389.x","article-title":"Analysis of safety and tolerability data obtained from over 1,500 patients receiving topiramate for migraine prevention in controlled trials.","volume":"9","author":"Adelman","year":"2008","journal-title":"Pain Med"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1600-0404.2007.00905.x","article-title":"Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study.","volume":"116","author":"\u00c7elebisoy","year":"2007","journal-title":"Acta Neurol Scand"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035545","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:31:17Z","timestamp":1746325877000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,20]]},"references-count":29,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035545","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,20]]}}}